News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Michael Hofman: 18F-CETO for primary aldosteronism
Michael Hofman/X
Feb 4, 2025, 17:03

Michael Hofman: 18F-CETO for primary aldosteronism

Michael Hofman, Nuclear Medicine Physician at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by Daniel Gillett et al. published in Journal of Nuclear Medicine:

“18F-CETO for primary aldosteronism: a promising adrenal gland PET/C T – can distinguish aldosterone-producing adenomas from normal adrenal tissue, thereby improving the evaluation and management of primary aldosteronism.

Very nice work from Daniel Gillett.”

“A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism”

Authors: Daniel Gillett, Russell Senanayake, James MacFarlane, Franklin Aigbirhio, Mark Gurnell et al.

Michael Hofman: 18F-CETO for primary aldosteronism

More posts featuring Michael Hofman.

18F-CETO aldosteronism cancer Daniel Gillett Franklin Aigbirhio James MacFarlane Mark Gurnell Michael Hofman OncoDaily Oncology primary aldosteronism Russell Senanayake
Special Coverage
Insight
Feb 4, 2025, 17:04
Hung Trinh: Oncolytic virus and CAR-T cell therapy in solid tumors
Science
Feb 4, 2025, 17:03
Michael Hofman: 18F-CETO for primary aldosteronism
Blog
Feb 4, 2025, 17:02
Axel S. Merseburger: When would you consider HR clinically meaningful in HRR allcomer population?
Science
Feb 4, 2025, 17:00
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors by Nikhil Vojjala et al.
Blog
Feb 4, 2025, 16:59
Luis E Raez: Celebrating the III International thoracic Cancer Debates
Science
Feb 4, 2025, 16:58
A retrospective study in EGFR+ NSCLC with brain metastases - Clinical Lung Cancer
Blog
Feb 4, 2025, 16:57
Julie McCrossin: What lessons has melanoma survivor, Karen van Gorp, learnt about advocacy
Blog
Feb 4, 2025, 16:54
Painting for Awareness and Hope by Cancer Fight Tanzania
Blog
Feb 4, 2025, 16:52
Chinmay Jani: EGFR mutation and treatment selection post-osimertinib progression at WLC25
Science
Feb 4, 2025, 16:52
DDR mutations and outcome in biliary tract cancers
Science
Feb 4, 2025, 16:48
Durable responses in SCLC with Tarlatamab by Jacob Sands et al. - ACS Journal Cancer
Science
Feb 4, 2025, 16:37
Eirini Papapetrou: Our new review article on leukemia stem cells